We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00893139
First Posted: May 5, 2009
Last Update Posted: July 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
  Purpose
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.

Condition Intervention Phase
Dry Eye Drug: AL-38583 ophthalmic solution 0.05% Drug: AL-38583 ophthalmic solution 0.10% Drug: AL-38583 vehicle Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean change from baseline in sodium fluorescein corneal staining score [ Time Frame: Baseline, up to Day 35 ]

Secondary Outcome Measures:
  • Mean change from baseline in phenol red thread length [ Time Frame: Baseline, up to Day 35 ]

Enrollment: 765
Study Start Date: June 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AL-38583 0.05%
AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
Drug: AL-38583 ophthalmic solution 0.05%
Experimental: AL-38583 0.10%
AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
Drug: AL-38583 ophthalmic solution 0.10%
Placebo Comparator: AL-38583 vehicle
Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
Drug: AL-38583 vehicle
Inactive ingredients used as a placebo comparator

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Composite corneal staining score of greater than 5 in one or both eyes.
  • Schirmer II score of greater than 4 mm.
  • OSDI score of greater than 23.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Any medical condition (systemic or ophthalmic) that may, in the opinion of the investigator, preclude the safe administration of the test article or safe participation in this study.
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00893139


Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Ravaughn Williams, OD, MS Alcon Research
  More Information

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00893139     History of Changes
Other Study ID Numbers: C-08-077
First Submitted: May 4, 2009
First Posted: May 5, 2009
Last Update Posted: July 15, 2014
Last Verified: July 2014

Keywords provided by Alcon Research:
Dry Eye

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Ophthalmic Solutions